In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Insmed Incorporated

Latest From Insmed Incorporated

With A Transformational Year Underway, Insmed Ramps Up

With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.

Clinical Trials Commercial

AN2 Looks To Shift Gears On Phase III Epetraborole Trial On Potentially Lackluster Results

The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.

Infectious Diseases Clinical Trials

Evaxion Cancer Vaccines Excite Investors

Shares in the Danish biotech have soared by 110% over plans to prioritize a novel category of AI-identified tumor antigens for its cancer vaccines.

Vaccines Artificial Intelligence

What Do FTC’s Aggressive Moves Against Biopharma Portend For 2024?

The Federal Trade Commission blocked or restricted several deals last year, broadening what it considers to be anticompetitive transactions. Stakeholders are looking to see if the agency will bring similar cases this year and what remedies it will seek to allow deals to go forward.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Pulmonary
      • Site Specific
  • Biotechnology
    • Large Molecule
    • Liposomes
  • Other Names / Subsidiaries
    • Insmed, Inc.
    • Transave Inc.